How CCHR helped secure a federal ban on school-coerced psychiatric drugging, fought for antidepressant suicide warnings, and advanced today’s push for safer deprescribing.
By CCHR International
The Mental Health Industry Watchdog
July 31, 2026
Citizens Commission on Human Rights International, the preeminent mental health industry watchdog that for decades has demanded full informed consent for antidepressants and other psychiatric drugs—as well as black box warnings about serious risks—reminds parents of a federal law the group helped secure in 2004. The Prohibition on Mandatory Medication Amendment prevents schools from forcing parents to place children on psychiatric drugs—primarily ADHD stimulants and antidepressants—as a condition of attending school.[1]
The amendment, part of the Code of Federal Regulations, was necessary because schools routinely coerced parents through threats of expulsion, Child Protective Services involvement, or criminal charges of medical neglect.[2] Many families saw children suffer severe side effects; some children and teens died by suicide while taking the drugs.
Simultaneously, CCHR pressed for disclosure of the suicide risks of SSRI antidepressants, as well as full disclosure of withdrawal dangers and the need for careful deprescribing. The long fight for disclosure and protection is now reflected in recent government actions. In May 2026, the U.S. Department of Health and Human Services announced efforts to curb psychiatric drug prescribing and to assist those wishing to withdraw safely from these drugs, especially antidepressants—a clear call for deprescribing.[3] On July 24, 2026, Florida Surgeon General Dr. Joseph A. Ladapo issued the “Avoidance of Psychotropic Pharmacotherapy in Children Age 5–17: Guidance Statement,” stating: “The State Surgeon General recommends against the use of psychotropic drugs in children for treatment of mental health conditions….”[4] In 2024, the UK government had already called for deprescribing and reduced use of antidepressants and other psychotropics.[5]
The Battle Between CCHR and the APA
When CCHR International campaigned for this protection, the American Psychiatric Association (APA) and several pharmaceutical industry-funded “patient rights” groups opposed it. One of the most prominent was Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD). The U.S. Drug Enforcement Administration had criticized CHADD for downplaying the risks of Ritalin and other stimulants while receiving substantial funding from manufacturers.[6]
In 2002, Government Reform Committee Chairman Dan Burton (R-IN) publicly criticized CHADD’s ties to drug companies, noting it had received $848,000 from one methylphenidate manufacturer alone.[7] In 2003, E. Clarke Ross, then-CEO of CHADD, stated in Psychiatric News: “Just remember that the Citizens Commission for Human Rights [CCHR] is behind the bill and is opposed to children being on any psychiatric medications.”[8] However, Mike Stokke, then deputy chief of staff to the Speaker of the House, confirmed with Insight magazine that school demands to drug children were widespread. “In case after case… we saw the coercive action of the state come in and say that the teacher says you have to take these drugs. And if you don’t it’s child neglect and the child is taken away from the parents.”[9]
A Roll Call article reinforced CCHR’s role in bringing the issue to Congress and noted that the psychiatric lobby was caught off-guard by the measure’s support. One industry lobbyist admitted the bill “caught the psychiatric community off-guard.”[10]
On May 21, 2003, the CMSA passed by a landslide vote of 425-1 in the House.[11] Despite industry opposition, it became law in 2004 with strong bipartisan support.
How the Law Was Won
The protection grew directly from CCHR’s work documenting cases of parents coerced into drugging their children with powerful mind-altering drugs under threat of school exclusion or medical neglect charges. Working with AbleChild.org and the National Foundation of Women Legislators, CCHR helped pass similar prohibitions in 12 states, building momentum for the federal effort.[12]
At the Government Reform Committee hearing in 2002, CCHR U.S. President Bruce Wiseman testified about mothers contacting CCHR about being coerced. “The abuse is tragic. Parents are being threatened with either criminal charges… or in some cases the loss of their children because they’re not put on mind-altering drugs…there are some children who aren’t permitted to go into school unless they’re on a mind-altering drug.”
Parent Patricia Weathers, co-founder of AbleChild, added: “Near the end of first grade, the school principal took me into her office and said that unless I agreed to put Michael on medication, she would find a way to transfer him to a special education center.” She went on to say, “Realizing that I was no longer willing to ‘fall in line’ and give my child drugs, the school threw him out. For a final blow, they proceeded to call child protective services on my husband and I, charging us with medical neglect for refusing to drug our child. This charge was later ruled unfounded.”
This hearing led to the Prohibition on Mandatory Medication law and remains in force today: “The State educational agency shall prohibit State and local educational agency personnel from requiring a child to obtain a prescription for a substance covered by the Controlled Substances Act as a condition of attending school.”
Congressman Burton praised CCHR’s efforts: “Through united action, effective education and advocacy, CCHR has helped to bring about critically needed healthcare reform.” Further, a senior staffer in the Committee of Government Reform added: “The most important impact CCHR has made was the increased awareness on Capitol Hill, on this issue; that we are forcing medication through schools.”[13]
Parallel Fight for Antidepressant Suicide Warnings
Simultaneously, CCHR pressed for disclosure of SSRI antidepressant risks, especially suicide.
In the 1980s, CCHR and law firms documented that the FDA already possessed substantial evidence that SSRIs could trigger severe adverse effects, including agitation, suicidal ideation, and violence. Internal company documents, clinical trial data, and a rapidly growing volume of adverse reaction reports pointed to these risks long before the drugs became household names.[14]
Through persistent Freedom of Information Act (FOIA) requests and litigation against the FDA, CCHR obtained and publicized critical safety data that regulators and manufacturers had withheld. While the psychiatric industry took no action on the mounting reports, CCHR filed a Citizen Petition with the FDA seeking to remove the drug from the market and pressed for greater scrutiny of the emerging safety signals.
This pressure contributed to the FDA’s decision to convene its Psychopharmacological Drugs Advisory Committee (PDAC) public hearing on September 20, 1991, to investigate antidepressant-induced suicide and violence. Dozens of patients and family members that CCHR assisted gave firsthand testimony describing how Prozac had triggered suicide attempts, completed suicides, and acts of violence. Despite this evidence, the majority of the panel—many of whom had financial ties to pharmaceutical companies and were granted conflict-of-interest waivers—chose to ignore it. The committee voted that there was no credible evidence linking antidepressants to suicidality or violence and recommended no label change.[15]
It would take another 13 years of dedicated work by CCHR, Prozac survivors, parents, attorneys, and whistleblowers before the FDA finally added the black-box warnings for suicidal ideation on SSRIs—warnings the American Psychiatric Association protested against.
A large volume of material had been kept from public view under FOIA Exemption 4 as trade secrets or confidential commercial information—Lilly’s internal clinical-trial analyses, data tables, and strategic memos. Those documents later surfaced through product-liability discovery and a 2004 leak to the British Medical Journal. They included a November 1988 Lilly report showing that 38% of Prozac patients experienced new “activation” symptoms (agitation, anxiety, insomnia) versus 19% on placebo, internal compilations indicating higher reported rates of suicide attempts and hostility compared with older antidepressants, and company discussions from the 1980s acknowledging these risks and considering how to limit their impact on labeling and prescribing.[16]
Following the 1991 hearing, CCHR intensified its efforts by submitting a broad FOIA request in June 1992 for all FDA records concerning Prozac, including the clinical trial data, New Drug Application files, and individual adverse-reaction reports. When the agency’s response proved incomplete, CCHR sued. In Citizens Commission on Human Rights v. Food and Drug Administration, 45 F.3d 1325 (9th Cir. 1995), the Ninth Circuit largely upheld the FDA and Eli Lilly on the adequacy of the search and most withholdings, but remanded on the individual adverse-reaction reports, which the agency conceded were not exempt.[17]
To this day, many psychiatrists and defenders of the field claim they “didn’t know” about the dangers. The data has been available all along for anyone willing to listen to patients or press for the facts. The psychiatric industry simply did not want to know.
Other Long-Called for CCHR Reforms Emerge
The 2026 Florida Surgeon General guidance also reinforced a CCHR initiative dating to its formation in 1969 and its Mental Health Declaration of Human Rights: the right to, and need for, a physical exam before initiating a “treatment” plan. The guidance further recommends first completing a full physical examination, including laboratory tests for nutritional disorders, endocrine disorders, heavy metals, mold exposure, and blood disorders.
As far back as 1982, CCHR campaigned for Senate Bill 929 in California, which established a pilot project to provide medical evaluation of people in public psychiatric hospitals.[18] CCHR was represented on the advisory committee established to oversee the pilot. The findings, officially published in 1989, showed that many patients studied had a physical disease that had been undiagnosed by mental health professionals and defined the medical tests that should be conducted.
Both the decades-long campaign for antidepressant black-box warnings and informed consent, and the successful fight for the Prohibition on Mandatory Medication Amendment—as well as recent objections to safe deprescribing—reveal the same pattern: the psychiatric industry, particularly the APA, has consistently prioritized the interests of Big Pharma over parental rights, patient safety, and medical freedom. Whether the issue was forcing parents to drug their children as a condition of schooling or suppressing evidence of suicide risks in antidepressants, the response has remained unchanged.
Anyone who continues to oppose meaningful reforms and greater informed consent in mental health—whether by defending the forced psychiatric drugging of schoolchildren or by downplaying the documented suicide risks of antidepressants—should be viewed through the lens of vested interest. Time and again, such opposition has aligned with the financial and professional priorities of the pharmaceutical industry and its psychiatric allies rather than the safety of patients and the rights of families. For more than four decades, the Citizens Commission on Human Rights International has stood as the independent mental health watchdog documenting these conflicts, exposing suppressed data, and fighting for parental and children’s rights and true informed consent. Those seeking accountability and protection from coercive psychiatric practices would do well to follow CCHR’s ongoing work.
[1] https://www.cchrint.org/issues/childmentaldisorders/prohibition-on-mandatory-medication/; § 300.174 Prohibition on mandatory medication, eCFR, 24 July 2026, https://www.ecfr.gov/current/title-34/subtitle-B/chapter-III/part-300/subpart-B/subject-group-ECFRad6c4bc24acb01c/section-300.174
[2] https://www.cchrint.org/2022/04/18/parents-rights-form-provides-opt-out-for-school-mental-health-screening/; “Protecting Children: The Use of Medication in our Nation’s Schools and H/R/ 170, Child Medication Safety Act of 2003,” House of Representatives, Subcommittee on Education Reform, Committee on Education and the Workforce, 6 May 2003, https://www.congress.gov/108/chrg/CHRG-108hhrg87723/CHRG-108hhrg87723.pdf
[3] https://www.cchrint.org/2026/05/11/hhs-announces-major-push-to-address-psychiatric-drug-risks/; “HHS Launches MAHA Action Plan to Curb Psychiatric Overprescribing,” U.S. Department of Health and Human Services, 4 May 2026, https://www.hhs.gov/press-room/hhs-launches-maha-action-plan-curb-psychiatric-overprescribing.html
[4] “Avoidance of Psychotropic Pharmacotherapy in Children Age 5–17: Guidance Statement,” Florida Department of Health, Office of the State Surgeon General. July 24, 2026
[5] Karin Smith, “Antidepressants, Question for Department of Health and Social Care,” UK Parliament, 12 Sept. 2024, https://questions-statements.parliament.uk/written-questions/detail/2024-09-12/5544
[6] https://www.cchrint.org/issues/psycho-pharmaceutical-front-groups/chadd/; “Methylphenidate (A Background Paper),” U.S. Department of Justice, Drug Enforcement Administration, Oct. 1995, https://www.ablechild.org/2014/03/23/drug-enforcement-administration-report-on-methylphenidate-ritalin/; Report of the International Narcotics Control Board, 1995, https://digitallibrary.un.org/record/213683?v=pdf, p. 28.
[7] https://www.cchrint.org/issues/psycho-pharmaceutical-front-groups/chadd/; Hearing before the Committee on Government Reform, House Of Representatives One Hundred Seventh Congress, Second Session, 26 Sep. 2002, https://www.congress.gov/107/chrg/CHRG-107hhrg83516/CHRG-107hhrg83516.pdf
[8] “Bill Would Regulate ADHD Discussions in School,” Psychiatric News, 16 May, 2003 (Volume 38, Number 1, https://psychiatryonline.org/doi/10.1176/pn.38.10.0010?__cf_chl_tk=90wlh09VrFcb2FOJwioWag9arPBzWEx_DoE3VgmDa1k-1784762906-1.0.1.1-MZNeE4b8pdj0Tkw9csFWyM6Z5AoGEir.SMSjStOPk4A; Kelly Patricia O’Meara, “Putting Power Back In Parental Hands,” Insight on the News, May 13, 2003,
[9] https://www.cchrint.org/2010/11/18/ablechild-unsung-hero-in-battle-against-psychopharmaceutical-industry/
[10] Emily Pierce, “Kennedy Takes Aim at Ritalin Provision,” Roll Call, 6 May 2003, https://rollcall.com/2003/05/06/kennedy-takes-aim-at-ritalin-provision/
[11] https://www.cchrint.org/2010/11/18/ablechild-unsung-hero-in-battle-against-psychopharmaceutical-industry/; House Congressional Record, H4387, 21 May 2003, https://www.govinfo.gov/content/pkg/CREC-2003-05-21/pdf/CREC-2003-05-21-pt1-PgH4387.pdf
[12] https://www.cchrint.org/2026/05/29/vindicated-cchrs-tireless-battle-for-psychiatric-drug-victims/; Minnesota House Bill 478, 1 Mar. 2001; Connecticut House Bill 5701, 28 Jun. 2001; Virginia House Bill 90, 1 Apr. 2002; Illinois House Bill 3744, 16 July 2002; Oregon Senate Bill 456, 2003; Texas House Bill 320, 20 June 2003; Texas House Bill 1406, 30 May 2003; Colorado House Bill 03-1172, 5 June 2003; Florida House bill 209, 2 May 2005; Florida Senate Bill 1766, 4 May 2005; Tenessee Senate Bill 850, 1 July 2009; New Mexico House Bill 53, 8 Apr. 2015
[13] https://www.cchrint.org/2026/05/29/vindicated-cchrs-tireless-battle-for-psychiatric-drug-victims/; Letter from Dan Burton to CCHR International on 20 Feb. 2009; Post-Interview Transcription, 2003
[14] SSRI Documents, Wisner Baum, https://www.wisnerbaum.com/advocacy_campaigns/ssri-documents/
[15] https://www.cchrint.org/2026/05/29/vindicated-cchrs-tireless-battle-for-psychiatric-drug-victims/; Miller v. Pfizer Inc.(Roerig Division), 196 F. Supp. 2d 1095 (D. Kan. 2002), https://law.justia.com/cases/federal/district-courts/FSupp2/196/1095/2517956/; Institute of Medicine (US) Committee to Study the Use of Advisory Committees; Rettig RA, Earley LE, Merrill RA, Food and Drug Administration Advisory Committees, Washington (DC): National Academies Press (US); 1992. 6, Ensuring Committee Integrity, https://www.ncbi.nlm.nih.gov/books/NBK236091/
[16] Jeanne Lenzer, “Documents missing from a 10 year old murder case sent to the BMJ,” The BMJ, 11 Dec. 2004, https://pmc.ncbi.nlm.nih.gov/articles/PMC535489/; Jeanne Lenzer, “FDA to review ‘missing’ drug company documents,” 1 Jan. 2005, https://pmc.ncbi.nlm.nih.gov/articles/PMC539828/
[17]CITIZENS COMMISSION ON HUMAN RIGHTS, Plaintiff-Appellant, v. FOOD AND DRUG ADMINISTRATION, Defendant-Appellee, and Eli Lilly and Company, Defendant-Intervenor-Appellee. No. 93-55818. United States Court of Appeals, Ninth Circuit, 18 Jan. 1995, https://openjurist.org/45/f3d/1325/citizens-commission-on-human-rights-v-food-and-drug-administration
[18] “NSH Studies Patient Diagnoses,” Undated/unnamed newspaper, circa July 1982; Lorrin M. Koran, M.D., et al., “Medical Evaluation of Psychiatric Patients,” Archives of General Psychiatry, Vol. 46, Aug. 1989, p. 733
SHARE YOUR STORY/COMMENT